Proton radiotherapy dose perturbations caused by esophageal stents of varying material composition are negligible in an experimental model

Background: Self-expanding metal and plastic esophageal stents (SEMS and SEPS, respectively) are used in conjunction with chemoradiation for palliation of malignant dysphagia. To date, the dosimetric effects of stents undergoing proton radiotherapy are not known.

Study aim: To investigate the proton radiotherapy dose perturbations caused by esophageal stents of varying designs and materials undergoing external beam treatment for esophageal cancer.

Patients and methods: Simulated clinical protocol. Solid acrylic phantom was used to mimic the esophageal tissue environment. Stents made of nitinol, stainless steel and polyester were tested. Proton beam dose of 2 Gy-E was delivered to each stent in a single anterior to posterior field. Film and image based evidence of dose perturbation were main outcomes measured.

Results: Only the stainless steel and plastic stents demonstrated slight overall dose attenuations (– 0.5 % and – 0.4 %, respectively). All the nitinol-based stents demonstrated minimal overall dose perturbations ranging from 0.0 % to 1.2 %. Negligible dose perturbations were observed on each of the stent surfaces proximal to the radiation source, ranging from – 0.8 % (stainless steel stent) to 1.0 % (nitinol stent). Negligible dose effects were also observed on the distal surfaces of each stent ranging from – 0.5 % (plastic and stainless steel stents) to 1.0 % (nitinol stent).

Conclusion: Proton radiotherapy dose perturbations caused by stents of varying designs and material composition are negligible. Negligible dose perturbation is in keeping with the inherent advantage of proton therapy over traditional radiotherapy composed of photons – given its relative large mass, protons have little side scatter.

• References

• 1 American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012
• 2 American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013
• 3 Javle M, Ailawadhi S, Yang GY et al. Palliation of malignant dysphagia in esophageal cancer: a literature based review. J Support Oncol 2006; 4: 365-373
• 4 Minsky B. Choosing the correct modality for the treatment of dysphagia in the patient with esophageal cancer. J Support Oncol 2006; 4: 377
• 5 Urba S. Dysphagia: we can relieve this symptom. J Support Oncol 2006; 4: 378-379
• 6 Coia LR, Soffen EM, Schultheiss TE et al. Swallowing function in patients with esophageal cancer treated with concurrent radiation and chemotherapy. Cancer 1993; 71: 281-286
• 7 Li XA, Chibani O, Greenwald B et al. Radiotherapy dose perturbation of metallic esophageal stents. Int J Radiat Oncol Biol Phys 2002; 54: 1276-1285
• 8 Chen YK, Schefter TE, Newman F. Esophageal cancer patients undergoing external beam radiation after placement of self-expandable metal stents: is there a risk of radiation dose enhancement?. Gastrointest Endosc 2011; 73: 1109-1114
• 9 Atwood TF, Hsu A, Ogara MM et al. Radiotherapy dose perturbation of esophageal stents examined in an experimental model. Int J Radiat Oncol Biol Phys 2012; 82: 1659-1664
• 10 Abu Dayyeh BK, VanDamme JJ, Miller RC et al. Esophageal self-expandable stent material and mesh grid density are the major determining factors of external beam radiation dose perturbation: results from a phantom model. Endoscopy 2013; 45: 42-47
• 11 Lee CT, Bilton SD, Famiglietti RM et al. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques?. Int J Radiat Oncol Biol Phys 2005; 63: 362-372
• 12 Suit H, Urie M. Proton beams in radiation therapy. J Natl Cancer Inst 1992; 84: 155-164
• 13 Suit HD. Protons to replace photons in external beam radiation therapy?. Clin Oncol (R Coll Radiol) 2003; 15: 29-S31
• 14 Weber DC, Rutz HP, Lomax AJ et al. First spinal axis segment irradiation with spot-scanning proton beam delivered in the treatment of a lumbar primitive neuroectodermal tumour. Case report and review of the literature. Clin Oncol (R Coll Radiol) 2004; 16: 326-331
• 15 Glimelius B, Isacsson U, Blomquist E et al. Potential gains using high energy protons for therapy of malignant tumours. Acta Oncol 1999; 38: 137-145
• 16 Seuntjens J, Olivares M, Evans M et al. Absorbed dose to water reference dosimetry using solid phantoms in the context of absorbed-dose protocols. Med Phys 2005; 32: 2945-2953
• 17 Shin JH, Song HY, Kim JH et al. Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma. J Vasc Interv Radiol 2005; 16: 67-74
• 18 Welsh J, Gomez D, Palmer MB et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 2011; 81: 1336-1342
• 19 Lin SH, Komaki R, Liao Z et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 83: e345-e351